In a previous study, we described a cell line (BRG-P) derived from a woman with Burkitt's lymphoma (BL) and acquired immunodeficiency syndrome that shared the same characteristic cytogenetic abnormalities as the patient's malignant cells. This cell line contained subclones that displayed an isotype switch from IgM t o lgAl and an accumulation of point mutations in the VH region genes. Because these two features suggested an antigen-driven process, we began a search for the antigen responsible for the stimulation of the malignant B cells. Specifically, we hypothesized that, because the patient's tumor had presented as a lymphomatous infiltration of the breast, the malignant B cells were recruited The majority of these BL cases are EBV-negative, although variations exist. Although EBV is believed to play a major pathogenetic role in endemic BL by promoting B-cell pr~liferation,~~'" it is more difficult to determine the driving forces that contribute to the expansion of EBV-negative BL cells in the presence or absence of human immunodeficiency virus (HIV) infection. However, the excessive B-cell activation occurring in HIV-seropositive individuals suggests a potential role for stimulating antigens derived from a variety of pathogens as well as for self-antigens in this process. The hypothesis that antigenic stimulation may be involved is supported primarily by the observation that, in BL cells, point mutations, resulting in significant amino acid substitutions, can be detected in the gene segments encoding for the complementarity determining regions (CDR) of the antibody H and L chains.''-'4 The localization of replacement substitutions in the CDR, and not in the framework, is thought to occur during antigen-driven proliferation of B cells and to require T-cell as~istance.'~-' ' The availability of a continuous cell line from an AIDS patient (BRG) with an EBV-negative BL provided the oppor- tunity to investigate the role of antigen stimulation in lymphomagenesis. The cell line (named BRG-P) expressed the same monoclonal A chains and shared the same cytogenetic and molecular features as did the malignant B cells isolated ex vivo. Other unique features of BRG-P included an isotype switch that had occurred in vivo and had yielded IgM and IgAl producing cell subclones in vitro and the presence of point mutations resulting in amino acid replacements in the CDRs of the H chain. Both events suggested that, in the course of maturation and lymphomagenesis in vivo, B cells were subjected to antigenic stimulation with the help of T cells."
In a previous study, we described a cell line (BRG-P) derived from a woman with Burkitt's lymphoma (BL) and acquired immunodeficiency syndrome that shared the same characteristic cytogenetic abnormalities as the patient's malignant cells. This cell line contained subclones that displayed an isotype switch from IgM t o lgAl and an accumulation of point mutations in the VH region genes. Because these two features suggested an antigen-driven process, we began a search for the antigen responsible for the stimulation of the malignant B cells. Specifically, we hypothesized that, because the patient's tumor had presented as a lymphomatous infiltration of the breast, the malignant B cells were recruited t o this site because of the reactivity of their surface Ig with breast tissue. A hybridoma (BRG-H) was obtained by fusing BRG-M cells (an IgM producing subclone of the BRG-P cell) with an appropriate cellular partner. The monoclonal antibody (BRG MoAb) produced by this hybridoma reacted strongly with t w o of five breast cancer cell lines and stained normal and malignant ductal epithelial cells on breast tissue sections. The antigen recognized by the BRG MoAb consisted of a single, minimally glycosylated polypeptide chain of 45 kD (~4 5 ) .
The BRG MoAb failed t o react with a panel
URKITT'S LYMPHOMA (BL) is a neoplasia charac-
B terized by cytogenetic and molecular abnormalities consisting primarily of a specific chromosomal translocation that causes the juxtaposition of the c-myc proto-oncogene with one of the genes encoding the H or the L chains of Ig.' ' The two types of BL, referred to as sporadic or endemic, differ in the prevalence of Epstein-Barr virus (EBV)-genome expression and in the topography of breakpoints of the chromosomal trans location^.^.^ There is an increased incidence of BL in acquired immunodeficiency syndrome (AIDS).'. ' The majority of these BL cases are EBV-negative, although variations exist. Although EBV is believed to play a major pathogenetic role in endemic BL by promoting B-cell pr~liferation,~~'" it is more difficult to determine the driving forces that contribute to the expansion of EBV-negative BL cells in the presence or absence of human immunodeficiency virus (HIV) infection. However, the excessive B-cell activation occurring in HIV-seropositive individuals suggests a potential role for stimulating antigens derived from a variety of pathogens as well as for self-antigens in this process. The hypothesis that antigenic stimulation may be involved is supported primarily by the observation that, in BL cells, point mutations, resulting in significant amino acid substitutions, can be detected in the gene segments encoding for the complementarity determining regions (CDR) of the antibody H and L chains.''-'4 The localization of replacement substitutions in the CDR, and not in the framework, is thought to occur during antigen-driven proliferation of B cells and to require T-cell as~istance.'~-' ' The availability of a continuous cell line from an AIDS patient (BRG) with an EBV-negative BL provided the oppor- tunity to investigate the role of antigen stimulation in lymphomagenesis. The cell line (named BRG-P) expressed the same monoclonal A chains and shared the same cytogenetic and molecular features as did the malignant B cells isolated ex vivo. Other unique features of BRG-P included an isotype switch that had occurred in vivo and had yielded IgM and IgAl producing cell subclones in vitro and the presence of point mutations resulting in amino acid replacements in the CDRs of the H chain. Both events suggested that, in the course of maturation and lymphomagenesis in vivo, B cells were subjected to antigenic stimulation with the help of T cells."
The aims of the present study were ( I ) to identify the 
MATERIALS AND METHODS
Description of the patient and derivation of lymphoma cell lines and of hybridomas. The case of patient BRG, a 30-year-old woman who was seropositive for HIV, was reported previously." The patient developed a mammary nodule that was diagnosed as a high-grade B-cell lymphoma. Peripheral blood (PB) smears and bone marrow biopsy at diagnosis showed the presence of a small number (2% to 5%) of Burkitt's-type (L3) leukemic blasts. Surface marker analyses of PB mononuclear cells (PBMC) showed a small population of cells that coexpressed lgMX, CD10, and CD38. The number of circulating neoplastic B cells increased during the course of the disease and the patient died of disseminated lymphoma. Chromosomal analyses showed a t(8; 14) translocation.
A B-cell line (BRG-P) was derived spontaneously from the patient's PBMC, as previously described." The majority of BRG-P cells expressed IgM and a minority were positive for surface IgAl .
Subclones that expressed only IgM or IgAl and that shared the same c-myc and Ig H chain gene rearrangements as BRG-P cells were obtained by limiting dilution.
Hybridomas were obtained by fusing the cells of one IgM producing subclone (BRG-M) with those of the SHM D-33 heteromyeloma cell line.'" 21 Hybridomas were selected in hypoxanthine, aminopterin, thymidine (HAT) medium (Seromed-Biochrom KG. Berlin, Germany) and ouabain (Sigma Aldrich, Milano, Italy) and cloned by limiting dilution. Supernatants of clones were screened for IgM production by an enzyme-linked immunosorbent assay (ELISA) and subsequently tested for their reactivity with various cell lines by immunofluorescence as described below. The supernatant of a single hybridoma (BRG-H) was selected for further testing. BRG-H cells shared the same H chain gene rearrangement as BRG-P parental cells, as shown by lg VH gene fingerprinting analyses (kindly performed by Dr Mariella Dono, as detailed in Wakai et al").
To purify IgM from the cell supernatants, BRG-H cells were cultured for 7 days in HyBM-ha medium (Promocell, Heidelberg, Germany) supplemented with SFM (Promocell). The supematants were concentrated in an ultrafiltration cell (Amicon, Co, Danvers, MA) and passed through a SephacryLS300 column (Pharmacia Biotech, Brussels, Belgium).
Immunojuorescence. The supernatant of BRG-H cells or its purified IgM fraction (from now on referred to as BRG monoclonal antibody [MoAb)) were used in indirect immunofluorescence tests. A mouse antihuman 1gM (Becton Dickinson & Co, San Josii, CA) was used as a second step reagent, and a fluorescein isothiocyanate (F1TC)-conjugated goat antimouse lgGl antibody was used as a third-step reagent (Southern Biotechnology Associates, Birmingham. AL). In control tests, the supematant of CLL 35.22 hybridoma was substituted for the BRG MoAb. This hybridoma was obtained by fusing IgMK-producing chronic lymphocytic leukemia cells with cells of the HMMA heteromyeloma cell line, as described." All samples of stained cells were analyzed by flow cytometry (FACScan; Becton Dickinson). In selected experiments, immunofluorescence was performed on cells preincubated in RPMI-1640 medium (Seromed) containing trypsin (I00 & n L ) (Sigma) or pronase (100 pg/ mL; protease VI; Sigma) for 1 hour at 37°C.
An anti-CD40 MoAb was kindly donated by Dr S.M. Fu (University of Virginia, Charlottesville, VA) and an anti-Apo-I/Fas/CD95 MoAb was a generous gift of Dr P. Krammer (DKFL, Heidelberg, Germany). Both MoAbs were used in indirect immunofluorescence as described."
Reactivity of BRG MoAb with antigens from pathogens or self antigens. The BRG MoAb was analyzed for its reactivity with double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), or rabbit y-globulin (RGG) by ELISA, as described." Reactivity against EBV viral capsid antigen (VCA; Dupont-DeNemours, Bad Hamburg, Germany), rubeola virus (Clone Systems, Bologna, Italy), cytomegalovirus (CMV; Clone System), toxoplasma (Clone System), and chlamydia (Sorin Biomedica, Vercelli, Italy) was assayed by ELISA. Reactivity for antigens from HIV-1, HIV-2, human Tlymphotropic virus-1 (HTLV-I), and HTLV-2 was determined by ELISA (Sanofi Diagnostics, Pasteur SA, Mames la Coquette, France) and Westem blot assays. Binding to poliovirus type 1, 2. or 3 was analyzed using neutralization tests. Reactivity to ifl blood group cold agglutinins was tested by hemagglutination using group 0' umbilical cord or adult human erythrocytes."
The following human cell lines were used: MDA-MB-468, MDA-MB-23 1, MDA-MB-I 57, MCF-7, and EVSA-T (from breast adenocarcinomas); HELA and A43 116 from cervical carcinomas; NEVO from skin carcinoma; and SKMEL28 from a melanoma. CALU1, CALU6, LC89, and AS49 were derived from lung carcinoma; N592 from a lung small cell cancer; Y79 from a retinoblastoma; HT 1080 from acetabulum fibrosarcoma; and KS from spindle cell Kaposi sarcoma. All these cell lines were obtained from the American Type Culture Collection (ATCC: Rockville, MD), except for EVSA-T and LC89, which were raised as detailed in Paganuzzi et aLZ4 MCF-7 and EVSA T-cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM; Seromed), whereas the others were cultured in RPMI-1640 medium. Media were supplemented with 10% fetal calf serum (FCS; Seromed), I Q glutamine, 1% Na piruvate, and 2% penicillin-streptomycin. One BL cell line (LAM) was originated from an AIDS patient, as previously reported,25 whereas the BJAB BL cell line was obtained from ATCC.
MDA-MB-468 cells were fractionated according to the expression of the antigen recognized by BRG MoAb, using an immunorosetting method described previously.*' Briefly, cells were sensitized with BRG MoAb, followed by a mouse lgGl antihuman IgM MoAb as a second-step reagent (Becton Dickinson). The cells were suhsequently rosetted with ox erythrocytes coated with a purified goat antimouse Ig antibody (Southern Biotechnology Associates) and rosettes were separated from nonrosetting cells by Ficoll-Hypaque density gradients.
Seven samples of breast tumors were studied. Four of these were invasive ductal carcinomas, one was an intraductal carcinoma (micropapillary variant), and two were invasive lobular carcinomas. Cryostat sections were air-dried and fixed with cold acetone for 5 minutes. After rinsing with Tris-buffered saline (TBS), sections were incubated for 1 hour at 4°C with a goat antihuman Ig antiserum (Southern Biotechnology Associates) to block human Ig infiltrating the tissue. Rinsing with TBS was followed by overnight incubation at 4°C with BRG MoAb. After
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another rinsing with TBS, sections were incubated for 45 minutes at 4°C with a 1:l mixture of a mouse IgGl antihuman IgM MoAb (Becton Dickinson; 1:lO in TBS) and of purified human IgG (1 mg/ mL in TBS). This step was followed by routine processing for alkaline phosphatase antialkaline phosphatase (APAAP), ie, sections were incubated for 30 minutes at 4°C with a rabbit antimouse Ig antiserum (Dako, Glostrup, Denmark) followed by APAAP for 30 minutes at 4°C. The alkaline phosphatase reaction was shown using a standard chromogen as the substrate (Naphtol AS-MX Phosphate and Fast Red TR salt; Sigma). Controls for the above-mentioned reactions included the incubation of sections with all of the reagents, either without the BRG MoAb or with a supernatant of the IgM CLL 35.22 hybridoma (see above).
Biochemical characterization of the antigen recognized by BRG MoAb. Cells (IO X lo6) from MDA-MB-468 or MCF-7 cell lines were lysed using RIPA (Triton I%, 150 mmol/L NaCl, 100 mmoU L Tris, pH 8, 2 mmol/L EDTA). Cell lysates were subsequently reacted with BRG MoAb (10 pg) or with control IgM (10 pg). These were monoclonal IgM purified from the sera of two patients with Waldenstrom macr~globulinemia.~' A goat antihuman IgM (Southern Biotechnology Associates) and Sepharose-bound protein A (Pharmacia) were subsequently added. The immunoprecipitates were pelleted and resuspended in 50 mmoVL Tris HC1, pH 6.8, 2% sodium dodecyl sulfate (SDS), 10% glycerol, and 0.01% bromophenol blue (with or without 4% 2-mercaptoethanel [2-ME]), sonicated, boiled, electrophoresed through 5% to 10% acrylamide gels, and electroblotted onto Hybond-C extra nitrocellulose membranes (Amersham International, Amersham, Bucks, UK). The membrane was probed with purified BRG MoAb, followed by a goat IgG antihuman-IgM (Cappel Organon Teknika Corp, West Chester, PA) and by "'Iprotein A (Amersham International). In control tests, purified monoclonal IgM were used instead of the BRG MoAb. The gels were exposed to Hyper-Film MP (Amersham International). The films were scanned with a Cannon CLC700 scanner (Cannon Inc, Costa Mesa, CA) and elaborated with an Adobe Photoshop 3.0 program (Adobe System Inc, Mountain View, CA).
Endogenous labeling was performed as previously described.28 Briefly, 10 x lo6 cells were cultured with 20 pCi/mL 35S-methionine-cysteine (Tran '%-label; ICN Pharmaceuticals Inc, Costa Mesa, CA) for 18 hours, harvested, lysed with Nonidet-P40 (NP40; Sigma), and analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). In selected experiments, cells were labeled in the presence of tunicamycin (25 pg/mL; Sigma).
BRG-M cells were resuspended at a concentration of 3 X lO'/mL in RPMI 1640 supplemented with 10% FCS (RPMI-FCS) and cocultured with MDA-MB-468 at the optimal BRG-MIMDA-MB-468 cell ratio of 4:l. In parallel experiments, apoptosis was induced by exposing BRG-M cells to F(ab'), fragments of rabbit IgG antibody to human p chains [F(ab'),-ap-Ab] coupled to polyacrylamide beads (Bio-Rad Laboratories, Richmond, CA), as previously described.2Y This reagent was used at a concentration of 10 pg/mL based on the results of preliminary titration experiments.
Apoptosis was measured by four different methods. First, permeabilized cells were stained with propidium iodide (PI; Sigma) and hypodiploid cells were enumerated by flow ~ytometry.'~ Second, DNA fragmentation was determined by electrophoresis according to a method previously described.2y Third, Giemsa-stained cytospin preparations were analyzed by light microscopy, and apoptotic cells were enumerated." Fourth, apoptotic cells were analyzed by electron microscopy. To this end, BRG-M cells were fixed with 2.5% glutaraldehyde (Polyscience, Warrington, PA) in O.lmol/L cacodylate buffer, pH 7.3, and post-fixed with 1% OsO, (Polyscience) in the same buffer. After en bloc staining with 1% uranyl acetate and dehydratation with ethanol and propylene oxide, samples were em-
Apoptosis assays.
bedded in LXll2 (Polyscience). Grey silver sections were stained with uranyl acetate and lead citrate, and observed with a Zeiss EM 1OC electron microscope (Zeiss, Oberkochen, Germany).
To block the binding of surface IgM to the specific antigen, BRG-M cells were incubated with a monovalent F(ab') fragment of rabbit IgG antibody to human p chains [F(ab')-ap-Ab] before being exposed to MDA-MB-468 cells as above. F(ab') fragments were prepared by digesting rabbit IgG with 1% pepsin (Sigma). The resulting F(ab'), fragments were purified on a Sephadex G150 column (Pharmacia) and subsequently reduced with 10 mmollL dithiothreitol (DTT) followed by alkylation with 30 mmoU L iodoacetamide (both from Sigma). Based upon the results of preliminary experiments, F(ab')-ap-Ab was used at a concentration of 50 pg/mL.
In other experiments, apoptosis was inhibited with CMOL. The supernatant of mCD40L-CD8-a hybridoma cell line, kindly provided by Dr. P. Lane (Basel Institute for Immunology, Basel, Switzerland) was used as a source of CD40L." This hybridoma produces a fusion protein composed of CD40-L plus CD8-a. BRG-M cells at the concentration of 3 X 10' in RPMI-FCS were cocultured with MDA-MB-468 cell line or with F(ab'),-ap-Ab, with or without CD40L supernatant at the final dilution of 1:20. This dilution was selected based on the results of preliminary titration tests. Cells were analyzed at several time intervals for the presence of apoptosis. (Fig 1) . The reactivity of the BRG MoAb was abrogated by pretreatment of MDA-MB-468 cells with pronase or trypsin, indicating that the surface antigen recognized by BRG MoAb was a protein (Fig 1) .
Inhibition ofapoprosis.

RESULTS
Reactivity of
BRG MoAb failed consistently to react with cells of four human lung carcinoma (CALU1, CALU6, LC89, and A549), one small-cell lung cancer (N592), one skin carcinoma (NEVO), one retinoblastoma (Y79), one melanoma (SKMEL28), one fibrosarcoma (HT1080), and one spindle cell Kaposi sarcoma (KS). A weak fluorescence staining with a small, but significant shift of the flow cytometry profile was observed with cells from one uterine cervical carcinoma (A43 16); another uterine cervical carcinoma cell line (HeLa) was negative (data not shown).
ELISA tests were also performed to determine the possible reactivity of BRG MoAb with a panel of self-antigens and exogenous antigens of common pathogens. These included dsDNA; ssDNA; RGG; and recombinant proteins of HIV-1, HIV-2, HTLV-1, HTLV-2, EBV, rubella virus, CMV, toxoplasma, and chlamydia. The results of all of these tests were consistently negative. Reactivity with HIV-1 and HIV-2 antigens, also tested by Western blotting, was negative. Agglutination tests for human red blood cell i and I antigens were negative as were the neutralization assays for poliovirus 1, 2, and 3.
Molecular characterization of the antigen detected by BRG MoAb. Initial attempts to characterize the molecule(s) in cell lysates reactive with BRG MoAb by standard Western blotting proved unsuccessful. To overcome these difficulties, the antigen(s) reactive with BRG MoAb were first immunoprecipitated from cell lysates and subsequently analyzed by immunoblotting on 10% acrylamide gels. A band of an apparent molecular mass of 45 kD was detected with this method in cell lysates of MDA-MB-468 cells. This band was present both in the gels run under reducing (data not shown) as well as under nonreducing conditions (Fig 2A) . This 45-kD band was never detected in the immunoprecipitates of MCF-7 cell lysates (Fig 2A) . thus confirming the immunofluorescence data. Several bands in the 50-to 60-kD regions were observed in the immunoprecipitates of both MDA-MB-468 and MCF-7 cell lysates obtained with both BRG MoAb and with the control monoclonal IgM, possibly indicating nonspecific binding of human IgM to certain cellular structures (Fig 2A) . The immunoprecipitates of cell lysates obtained with BRG MoAb were analyzed by immunoblotting using 5% gels. These analyses consistently failed to show molecules of a molecular mass greater than the 45-kD band described above. Thus, the 45-kD band was the only antigen recognized specifically by BRG MoAb.
In another set of experiments, MDA-MB-468 cells were cultured for 18 hours in the presence of a mixture of "Slabeled methionine and cysteine. Cell lysates were subsequently immunoprecipitated with BRG MoAb or with two control human monoclonal IgM and analyzed by SDS-PAGE. Three or four bands were consistently observed in the 50-to 60-kD region in all of the immunoprecipitates, irrespective of the IgM reagent used for immunoprecipitation. However, a band corresponding to a molecular mass of 45 kD was detected only in the lysates immunoprecipitated with BRG MoAb, confirming its specificity for this
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IgM IgM BRG 1 2 mAb For personal use only. on September 14, 2017. by guest www.bloodjournal.org From molecular structure (Fig 2B) . The mobility of the specific band did not change when SDS-PAGE was run under reducing conditions (data not shown), thus indicating that the protein antigen detected by BRG MoAb consisted of a single polypeptide chain. Moreover, the SDS-PAGE mobility of the 45-kD band did not change when cells were endogenously labeled in the presence of tunicamycin, which inhibits Nlinked glycosylation. This indicates that the 45-kD protein was minimally N-glycosylated. Because of these findings and for the sake of brevity, from this point the antigen detected by BRG MoAb will be referred to as p45.
Reactivity of BRG MoAb with breast tissue. We next tested the capacity of BRG MoAb to stain tissue sections of breast carcinomas (Fig 3) . A moderate to strong reactivity of the BRG MoAb was detected in the cells of alveolar ducts of both ductal (Fig 3A and C) and lobular carcinomas, whereas alveolar cells in invasive lobular carcinomas were consistently negative (data not shown). The reactivity of ductal cells in sections of invasive lobular carcinomas also indicated that p45 was expressed in normal as well as in malignant ductal epithelial cells. This notion was reinforced by observation of apparently normal alveolar portions of the gland that were present in the periphery of invasive ductal cancers. Here, the ducts were stained by BRG MoAb, whereas the alveolar portions of the gland displayed a negative or negligible reaction (Fig 3E and F) . l) , yielded an almost pure population of p45-cells. Flow cytometry analyses showed that these cells maintained the p45-phenotype for 3 to 4 days after the separation procedure (data not shown).
BRG-M cells were cocultured with MDA p45+ or MDA p45-cells and analyzed for apoptosis. Because both MDA p45+ and MDA p45-cells were tightly adherent to the plastic surfaces, whereas BRG-M cells remained in suspension, it was possible to obtain, at the end of the culture period, cells that were composed predominantly of BRG-M cells, thus facilitating the evaluation of their apoptotic process. BRG-M cells were first stained with PI and analyzed by flow cytometry. Fifty percent to seventy percent of the BRG-M cells cocultured with MDA-p45+ cells underwent apoptosis (Fig 4A) . These values were observed after 24 hours in culture and remained virtually unchanged for the next 72 hours. In contrast, only rare BRG-M cells cocultured with MDA p45-cells were apoptotic. These findings were confirmed by DNA electrophoresis and by morphologic analyses, both at the light and at the electron microscopy level. DNA laddering and nuclear fragmentation, characteristic of apoptosis, were observed only in BRG-M cells cocultured with MDA-p45+ cells for 24 hours (Fig 4B and C) . Electron microscopy analysis showed typical ultrastructural features of apoptotic cells in the BRG-M exposed to MDA-p45+ cells (Fig 4D) . Notably, MDA p45+ cells did not undergo apoptosis irrespective of whether they were cultured in the presence or in the absence of BRG-M cells. This was determined by morphologic as well as by PI staining analyses on adherent MDA-p45+ cells recovered from the culture plates (data not shown).
Additional experiments confirmed that both the p45 mole- Apoptosis of BRG-M cells is prevented by F(ab')-ap-Ab. In subsequent experiments, BRG-M cells were exposed to a F(ab')-ap-Ab at 4°C for 1 hour before coculture with MDAp45' cells. Cells were cocultured for 24 hours at 37°C before PI-staining and flow cytometry analysis of recovered BRG-M cells. Unlike the divalent F(ab')2-ap-Ab that induced apoptosis of the majority of BRG-M cells (Fig 5) , F(ab')-ap-Ab failed to induce apoptosis of BRG-M cells (Fig 5) . This is consistent with the inability of this reagent to crosslink the cell surface IgM. However, the presence of F(ab')-ap-Ab inhibited substantially the apoptosis induced by MDA-p45+ cells. Therefore, it appears that F(ab')-ap-Ab, by inhibiting the binding of surface IgM to the p45 molecules, also prevented the delivery of the apoptotic signal.
BRG-M cells are rescued from apoptosis by CD4OL. Upon binding to its complementary structure (CD40) on the B-cell surface, CD4OL prevents apoptosis of certain B-cell subsets such as germinal center ~el1s.l~ In these experiments, we tested whether apoptosis of BRG-M cells induced by exposure to MDA-p45+ cells could be inhibited by CD40L. Immunofluorescent studies showed that BRG-M cells expressed abundant surface CD40, as is typical for BL cells (data not shown and Holder et a13'). BRG-M cells were exposed to MDA-p45+ cells in the presence or absence of CD40L. Cells were cultured for 24 hours, harvested, PIstained, and analyzed for apoptosis by flow cytometry (Fig  6) . Whereas exposure to MDA-p45+ cells caused apoptosis of a large fraction of cells (50% to 70%), the presence of CD40L resulted in almost complete inhibition of apoptosis. CD40L also inhibited apoptosis of BRG-M cells induced by F(ab'),-ap-Ab (Fig 6) . antibodies, thus indicating that the BRG MoAb had a restricted range of specificity. Finally, the BRG MoAb failed to react with cells from a panel of human cell lines mainly of epithelial origin, with the exception of those from human cervical carcinomas.
Immunohistochemical observations of breast sections showed that p45 was expressed selectively by ductal cells, both malignant and normal. Although normal tissue samples were not available, this conclusion was derived from analyses of normal alveolar tissue that surrounded ductal tumors and of uninvolved ductal epithelium present in lobular carcinomas. Because histopathologic analyses indicated that the patient did not have breast cancer, the native p45 autoantigen The outcome of the process initiated in vitro by the encounter between p45 and its specific receptor on the BRG-M cell surface (ie, cell death or cell rescue) appeared to be dictated by the availability of CD40L. Because CD40L is expressed on the surface of activated T cells'"" as well as of other cells such as basophils or mast cells:* the collected evidence suggests that such CD40L-expressing cells may have been involved in the pathogenesis of BRG lymphoma in vivo. Unfortunately, the paucity of circulating T cells and the rapidly deteriorating clinical conditions of the patient prevented studies on the T-cell response to p45 peptides or to other antigens from breast cells. However, the aforementioned observations of accumulation of somatic mutations in the VH gene segments encoding the antibody CDR and the isotype switch from IgM to IgAI" provide an indirect support for T-cell participation in the maturation of these cells and possibly in lymphomagenesis. In this regard, it is of note that IgAl-producing clones of BRG-P cell line maintained their specificity for p45 and were induced into apoptosis upon coculture with p45 expressing cells (data not shown). Thus, the process of intraclonal maturation detected in the lymphoma cells" did not significantly alter their antigenic specificity, despite the apparent disadvantage imposed by the expression of a receptor capable of delivering apoptotic signals. These disadvantages were possibly counterbalanced by the advantages provided by CD40L. These advantages may have also prevented any additional form of receptor editing by the lymphoma cells.".54
Analyses of the c-myc rearrangement showed that the breakpoint on chromosome 8 involved the c-myc gene rather than flanking sequences, whereas the breakpoint on chromosome 14 involved the JH locus.",5s This rearrangement likely resulted from recombinase errors before membrane Ig receptor expression. Thus, this rearrangement was an early event in the process of transformation, a finding that is also consistent with the observation that the same c-myc translocation characterized both the IgM-and IgAl -producing clones. ' '
Therefore, it appears that antigenic stimulation occurred after the major cytogenetic changes characteristic of all BL. Whether and how the presence of the rearranged c-myc facilitated the onset of an autoimmune reaction directed to p45 remains to be seen.
The present findings offer a number of clues to explain some of the phenomena occurring in AIDS patients with BL. For example, these observations support the notion that antigenic stimulation is a relevant predisposing factor for BL pathogenesis. Moreover, the requirement for the help of CD40L-expressing cells is consistent with the observation that BL may arise in HIV-seropositive patients before impairment of the immune system becomes Moreover, because CD40L-expressing cells other than T cells presumably are not deleted by HIV, there is a large window of rescue. The antigenic stimulation supporting the pathogenesis of lymphomas may involve HIV-related antigens or antigens of opportunistic microorganisms, or even selfantigens, thus reinforcing the concept that immune dysregulation caused by HIV may concomitantly induce autoimmunity and neoplasia.
